All Stories

FDA rejects Hengrui, Elevar's PD-1 cancer drug combinat...

The FDA has once again issued a complete response letter to Hengrui and Elevar’s...

#FierceMadness: The 2025 Drug Ad Tournament heats up in...

As the college basketball March Madness tournament gets underway, so too does Fi...

Novartis links music and science in corporate campaign ...

A Big Pharma may seem like an incongruous choice of sponsor for a global music c...

J&J touts $55B in planned US investments over 4 years, ...

Johnson & Johnson will invest $55 billion in the U.S. over the next four years. ...

Novartis snags FDA nod for Fabhalta in another kidney d...

Novartis' Fabhalta has become the first treatment approved by the FDA for the ul...

Regulatory tracker: Hutchmed bags approval for lymphoma...

In this tracker, Fierce Pharma is recording the regulatory progress of in-market...

Fierce Pharma Asia—AstraZeneca-Alteogen drug delivery d...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Ta...

A closer look at pharma’s top patent losses in 2025

This week on "The Top Line," we explore the potential impacts of this year's siz...

J&J advances Stelara succession scheme with FDA nod for...

The FDA approved Tremfya as an induction therapy in adults with moderately to se...

Biotech designed to commercialize Ascendis' endocrinolo...

Endocrine-disease-focused Visen Pharmaceuticals is making its public market debu...

J&J advances Stelara succession scheme with key FDA nod...

The FDA approved Tremfya as an induction therapy in adults with moderately to se...

Novartis plans 427 layoffs as looming Entresto patent c...

Novartis is laying off 427 employees who report to its headquarters in East Hano...

Alnylam's Amvuttra wins key approval in ATTR-CM, teeing...

Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM...

Lilly backs study in mission to improve Hollywood repre...

Hollywood has in recent years been undergoing a much-needed, long-awaited transf...

Calling UK 'uninvestable,' pharma giants demand revamp ...

Global pharma giants AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Novar...

ConsensusMD: How peer-to-peer knowledge sharing is addr...

ConsensusMD: How peer-to-peer knowledge sharing is addressing healthcare's most ...

Paratek acquires Optinose, rhinosinusitis spray Xhance ...

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals ha...

Investor group calls for strategy shift as Amarin share...

Two "concerned shareholders" are calling for an immediate strategic review at Am...

Calling UK ‘uninvestable,’ pharma giants demand revamp ...

Global pharma giants AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Novar...

South Africa's Aspen hit with warning letter chiding th...

Aspen Pharmacare, the largest drugmaker on the African continent, was slammed in...

AstraZeneca offers early look at Datroway-Tagrisso comb...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway ...

'Pick Up Your Poop': A potty-mouthed dog flips the scri...

The campaign asks why people readily pick up their dogs’ poop while putting off ...

Pfizer enlists Elizabeth Banks for Gen X-focused pneumo...

In an attempt to strike a pitch-perfect tone with Generation X, Pfizer has recru...

CDMO Delpharm gets cash infusion from Canada to help mo...

Equipped with a 60-million-Canadian-dollar ($42 million) investment from the Can...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.